The drug cost to the National Health Service for a one year supply of Apomorphine for a patient with Parkinson's Disease is estimated to be in the region of £5,300 and £9,000, based on the usual daily dose of 3 \u2013 30mg. However, the maximum daily is 100mg, so the annual cost for some patient\u2019s treatment may be higher.<\/p>
We have no estimate of the cost of manufacture. We are not aware of any particular issues relating to the manufacture of this drug. Pharmaceutical companies participate in either the voluntary pharmaceutical price regulation scheme (PPRS) or the statutory medicines price regulation scheme, both of which regulate the cost of medicines to the NHS. Products covered by the statutory scheme are subject to a 15% cut to their list price. Companies in the PPRS pay a percentage of sales to the Government when growth in NHS spending on medicines exceeds an agreed level. NHS purchasers may also negotiate discounts with pharmaceutical companies in addition to national price regulation.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4545", "label" : {"_value" : "Biography information for Lord O'Shaughnessy"} } , "answeringMemberPrinted" : {"_value" : "Lord O'Shaughnessy"} , "dateOfAnswer" : {"_value" : "2017-07-19", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-19T15:12:09.617Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-07-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Parkinson's Disease: Drugs"} , "houseId" : {"_value" : "2"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25277", "prefLabel" : {"_value" : "House of Lords"} } ], "questionText" : "Her Majesty's Government how much the NHS pays for a one year supply of Apomorphine for a patient with Parkinson's Disease; how much they estimate it costs to manufacture a year's supply of that drug; what assessment they have made of the difficulties of manufacturing Apomorphine to clinical standards; and whether they intend to take any steps to reduce the cost of that drug to the NHS.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1879", "label" : {"_value" : "Biography information for Lord Lucas"} } , "tablingMemberPrinted" : [{"_value" : "Lord Lucas"} ], "uin" : "HL914"} , {"_about" : "http://data.parliament.uk/resources/752671", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/752671/answer", "answerText" : {"_value" : "
NHS England will develop evidence based treatment pathways across mental health services over the next five years in line with the recommendations of the Five Year Forward View for Mental Health. NHS England is working with the National Institute for Health and Care Excellence and the National Collaborating Centre for Mental Health to ensure that each pathway is fully informed by the available evidence and the views of experts by experience.<\/p>
<\/p>
The National Collaborating Centre for Mental Health is developing a pathway for adults with eating disorders, together with detailed implementation guidance for providers, over 2017/18.<\/p>
<\/p>
NHS England is also conducting a baseline audit to measure existing levels of investment, capacity and activity across inpatient and community services for adults with eating disorders.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2017-07-19", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "5008"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2017-07-19T13:23:22.317Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health"} , "answeringDeptSortName" : {"_value" : "Health"} , "date" : {"_value" : "2017-07-17", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Eating Disorders"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health, what assessment he has made of the potential merits of introducing service standards for adults suffering from eating disorders for (a) access to services and (b) waiting times.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4478", "label" : {"_value" : "Biography information for Royston Smith"} } , "tablingMemberConstituency" : {"_value" : "Southampton, Itchen"} , "tablingMemberPrinted" : [{"_value" : "Royston Smith"} ], "uin" : "5142"} , {"_about" : "http://data.parliament.uk/resources/752673", "AnsweringBody" : [{"_value" : "Department of Health"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/752673/answer", "answerText" : {"_value" : "
This information is not available in the format requested. NHS England publishes quarterly England only level data on waiting times for children and young people with an eating disorder. It can be accessed via the following link:<\/p>